Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma
Scott A. Ezell(AstraZeneca (United Kingdom)), Kate F. Byth(AstraZeneca (United Kingdom))
Cited by 54
Related Papers
The cellular phenotype of AZ703, a novel selective imidazo[1,2-<i>a</i>]pyridine cyclin-dependent kinase inhibitor
|Molecular Cancer Therapeutics|2006|48